Araclon Biotech is a small company founded in 2004 dedicated to the research and development of therapies and diagnostic methods for Alzheimer’s disease. Even though being a small company, Araclon is part of Grifols, being the major shareholder, so it has been classified as a large business.
Currently we offer the quantification of Alzheimer’s Disease relevant Aβ42 and Aβ40 peptides in plasma by two proprietary methods: ELISA and Liquid-Chromatography-Mass Spectrometry assays. These assays are carried out as a service at our facilities in Spain and US.